15 (0.075) g/kg/min for 48h. Within 24h on admission, patients underwent CAG or CAG+PCI. The angiographic results (initial TIMI, final TIMI/CTFC/TMPG) were evaluated.

Platelet aggregation rate (PAR) was measured before and 2, 24, 48h after bolus tirofiban. MACEs were evaluated at S3I-201 JAK/STAT inhibitor 7-day, 30-day, and 6-month follow-up. Bleeding was observed at 7days.\n\nResults The proportions of TIMI grade 3 seemed higher in SD group before and after PCI followed by a better myocardial perfusion, but not statistically different (P=0.26/0.08). PAR was lower in SD group than that in HD group at 2h after bolus tirofiban (P=0.03). MACEs were not statistically different at 7, 30day, and 6month in two groups. The incidence of minor bleeding was significantly lower in HD group than that in SD group (8.2% vs. 20.5%, P=0.04). The risk of bleeding would increase under the conditions of decreased PAR, increased dose of tirofiban and decreased VS-6063 nmr CCr.\n\nConclusion Half-dose tirofiban

was not inferior to standard-dose in efficacy, what is more, half-dose tirofiban showed a better safety characteristic of lower bleeding risk. Therefore, half-dose tirofiban is recommended to patients with NSTE-ACS undergoing early PCI.”
“Background: HMG-CoA reductase inhibitors (statins) can effectively reduce serum low-density lipoprotein cholesterol (LDL-C) levels in the majority of patients at increased cardiovascular risk. However, some patients at increased cardiovascular risk have a high peripheral leukocyte count and this inflammatory marker has correlated with an increased incidence of coronary events. Recently, in a large clinical trial-based cohort, an increasing on-statin cholesteryl ester transfer protein (CETP) mass was inversely related

to coronary events, particularly among those with a low serum LDL-C level. However, the role of the CETP mass in the development of atherosclerosis is still unclear.\n\nObjective: We investigated the possibility of whether the CETP mass was associated with the peripheral leukocyte count after intensive statin therapy, and whether the CETP mass was changed by switching statins.\n\nMethods: This study was an open-label lipid interventional study switching from atorvastatin to pitavastatin without www.selleckchem.com/products/tariquidar.html a washout period. Between 1 April 2010 and 31 March 2011, 32 patients (mean age 64.0 +/- 9.0 years, 63% male) with hypercholesterolemia receiving atorvastatin (10 mg/day) were enrolled. Next, they were switched to pitavastatin (2 mg/day) for 6 months. The peripheral leukocyte count, the CETP mass measured by enzyme-linked immunosorbent assay, and lipid parameters were measured at baseline and at follow-up. The type and dosage of concomitant drugs were not changed during the study periods.\n\nResults: The on-atorvastatin LDL-C level was well controlled with 94.4 +/- 23.1 mg/dL, and peripheral leukocyte count was 6209 +/- 1142 cells/mu L.